Navigation Links
New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension

-FIXED DOSE COMBINATION WITH DIURETIC ACCEPTED FOR REVIEW BY FDA-

BASEL, Switzerland and BRIDGEWATER, NJ, 21 May 2007 - Speedel (SWX: SPPN) today welcomed the significant new results from clinical trials of SPP100 (aliskiren, Tekturna/Rasliez[1]) presented by investigators at the 22nd Annual Scientific Meeting and Exposition of the American Society of Hypertension (ASH) in Chicago, IL, USA. These results confirm the favourable safety and efficacy profile, as well as the potential advantages of this first-in-class once daily direct renin inhibitor for the treatment of hypertension.

Tekturna was approved by the US Food and Drug Administration (FDA) and launched by Novartis in the US in March 2007 to treat hypertension both as monotherapy and in combination with other anti-hypertensives. In September 2006, SPP100 was also submitted by Novartis to the European Medicines Agency (EMEA) for review in the European Union. Speedel successfully developed SPP100 through Phase I and II clinical trials before Novartis exercised its license-back option in 2002.

Dr. J. Chris Jensen, Speedel Head of Scientific Affairs, commented: "The extensive data presented at this important scientific meeting highlights the potential of SPP100 as the next gold standard in the treatment of hypertension. It is particularly encouraging to note that SPP100 is the only anti-hypertensive therapy which lowers blood pressure and plasma renin activity, irrespective of the amount of renin circulating in the bloodstream."

Speedel also welcomes the announcement today by Novartis that the FDA has accepted for regulatory review the fixed dose combination of Tekturna with the diuretic HCTZ[2]. Single pill fixed dose combinations of different therapies, particularly a diuretic, are commonly used to help patients achieve their blood pressure goals and to improve patient compliance. The submission of Tekturna HCT[3] was base
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
4. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
5. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
6. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
7. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
8. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
9. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
10. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
11. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
Post Your Comments:
(Date:5/15/2008)...Results Confirm Efficacy for Population Most Affec...if., May 16 /-,Bayer Health...s, Inc.,(Nasdaq: ONXX ) today announced that Nexa...overall survival by 47.3 percent (HR=0.68;,p-value...h advanced,hepatocellular carcinoma (HCC), or prim...
(Date:5/15/2008)...RANCISCO, May 15 /- Medivat...ta from an ongoing Phase 1-2 clinical,trial of its... be presented,in an oral presentation at the 44th ...l Meeting in Chicago., Session title: New Targe...Session date and time: Monday, June 2 at 11:30 a.m...
(Date:5/15/2008)...I Data Presented at ASCO Showed Acceptable Tolerab...rade 3 and 4 Neuropathy, WOODCLIFF LAKE, N.J., Ma...apeutic agent eribulin mesylate (E7389) demonstrat...women with locally advanced or metastatic,breast c...e II clinical,trial. The study also suggests that ...
(Date:5/15/2008)...WORTH, N.J., May 15 /- Sche... advancing the science and treatment of,chronic he...hat data from,several clinical studies with PEGINT...bavirin, USP) combination therapy, as well as boce...tease inhibitor, will be presented at,the 39th ann...
Breaking Medicine Technology:Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Ocera Therapeutics Announces Positive Results with AST 120 in Pouchitis 1265 1Ocera Therapeutics Announces Positive Results with AST 120 in Pouchitis 1265 2Ocera Therapeutics Announces Positive Results with AST 120 in Pouchitis 1265 3Genetic approach provides new insight into trastuzumab resistance in breast cancer 3688 1Genetic approach provides new insight into trastuzumab resistance in breast cancer 3688 2THA Honors Nine Legislators for Contributions to Health Care 3684 1THA Honors Nine Legislators for Contributions to Health Care 3684 2Clubhouse of Suffolk to Host 15th Annual Mental Illness Awareness Day 3680 1Clubhouse of Suffolk to Host 15th Annual Mental Illness Awareness Day 3680 2
... analysis of Phase 2 comparative study showed sign...if, CAMBRIDGE, Mass. and WAYNE, N.J., May 02, 2007... Bayer HealthCare,Pharmaceutical today announced d...study. This interim analysis of all patient data,t...of the study for,all patients showed that a once-y...
...G, Germany, May 03, 2007 /PRNewswire/ -- At the Ap...which provide a sound,scientific basis for a new d...ents. , Tumor tissue-derived primary cell lines ar...ng. During their clonal selection and,expansion, h...,change significantly, thereby losing many of thei...
Other Medicine Technology:Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 2Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 3Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 4Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 5Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 6Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 7Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 8Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 9Indivumed Study Provides Sound Scientific Basis for a Predictive,Drug Test- Platform 2
(Date:5/17/2008)...t report could not establish safe-limit price as g..., May 17 (HealthDay News) -- Those inexpensive ear...y be good for your wallet but bad for your ears an... earrings sold for less than $50 by local San Fran... cause dermatitis on the earlobes and repeated exp...
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)... Contract Covers More than 500 Workers, WASHINGT...0 paramedics,and emergency medical technicians in ...gton area have ratified their first-ever contract ...ese workers are now covered by a,strong contract t...ent,future," said Teamsters General President Jim ...
(Date:5/16/2008)...Small fibroids located just beneath the lining of ... the endometrial cavity after uterine artery embol...ations, according to a new study. , The study i...t an MRI examination before and after UAE. The stu...e, 33% migrated to the endometrial cavity after UA...
Breaking Medicine News(10 mins):Health News:Cheaper Earrings More Likely to Contain Nickel 2Health News:Cheaper Earrings More Likely to Contain Nickel 3
... the AMA Rural Reference Group (AMARRG), Dr David ...y Transport Minister, Warren Truss, //of enhanceme...) was a welcome piece of rare good news for rural ...igned to attract GPs to work in country areas and ...
...xperts at University of Iowa are taking efforts to...cribed only when really needed.// Salmeterol is a...on with a corticosteroid, which is inhaled. The us...iorate the asthma for a few people with that condi...
...ers have uncovered important information about how... a critical step in DNA mutation that has eluded r...rs in the August edition of the Journal of the Ame... Institute of Technology have reported uncovering ...
...e about three severe, potentially fatal genetic di...that they can rupture in pregnancy and labor or ev...a blockers, curbing exercise, proactive blood vess...be helpful, but their usefulness varies according ...
Other Medicine News:Health News:RMIF Boost a Boon for Rural Health 2Health News:Salmeterol - to be used in combination & only when required 2Health News:Salmeterol - to be used in combination & only when required 3Health News:Elusive Step In DNA Mutation Uncovered By Researchers 2Health News:Elusive Step In DNA Mutation Uncovered By Researchers 3Health News:Elusive Step In DNA Mutation Uncovered By Researchers 4Health News:Scientists Review Loeys-Dietz Syndrome in the Largest Ever Study to date 2Health News:Scientists Review Loeys-Dietz Syndrome in the Largest Ever Study to date 3
For use with 8 channel pipets.
...sign, manually adjustable dispensing head, and dis...e brings unparalleled flexibility and cost-efficie...t instrument of its kind to offer fast dispensing ...,000L). It also offers the added benefit of being ...
...atented non-contact dispensing technique that coup...valve and stage stepper motor. synQUAD dispenses a...lides, plates, or membranes. At 100 nL dispense vo...less than 10%. An 8-channel synQUAD system dispens...
The WP1000S is a shortened base version of the WellPro that is shortened 5 inches to facilitate fitting into smaller biohazard hoods.
Medicine Products: